CCCC C4 THERAPEUTICS
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 12 analyst firms say about C4 THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
11 rated views · 12 analyst/firm records · 12 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 6 reports on CCCC from 6 analyst firms in the last 90 days (12 firms in the past year).
Comparing each firm's latest target with its previous one: 5 have their first observed target in the past year.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Etzer Darout | Buy | 3 Aug 2026 | 7.00 USD |
| Brookline Capital | Unnamed analyst | Buy | 23 Feb 2026 | 30.00 USD |
| Brookline Capital Markets | Leah R Cann | Buy | 11 Aug 2026 | 30.00 USD |
| Evercore ISI | Gavin Clark-Gartner | Buy | 1 Jun 2026 | 12.00 USD |
| Guggenheim | Bradley P Canino | Buy | 18 Sep 2026 | 7.00 USD |
| Jefferies | Akash Tewari | Buy | 1 Apr 2026 | 14.00 USD |
| JPMorgan | Anupam Rama | Buy | 9 Oct 2026 | 10.00 USD |
| Lake Street Capital Markets | Chad Messer | Buy | 28 Oct 2026 | 11.00 USD |
| TD Cowen | Tyler Van Buren | Buy | 15 Jun 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Wells Fargo | Derek C Archila | Buy | 26 Aug 2026 | 10.00 USD |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:58 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.